Logo

Janssen's Stelara (ustekinumab) Receives EC's Approval for its Expanded Use to Treat Moderately to Severely Active Ulcerative Colitis

Share this

Janssen's Stelara (ustekinumab) Receives EC's Approval for its Expanded Use to Treat Moderately to Severely Active Ulcerative Colitis

Shots:

  • The EC approval is based on P-III UNIFI program [induction study (8wks. IV) & maintenance study (44wks.- SC- q8w & q12w)] assessing Stelara vs PBO in patients with mod. to sev. active UC with inadequate response to conventional (corticosteroids- immunomodulators) or biologic (one or more TNF-alpha antagonists/vedolizumab) therapies
  • Induction study results: Clinical response achievement (62% vs 31%); achievement of normal stool frequency and had no bleeding. Maintenance study results: sustained effect (57.4% & 48.3% vs 35.4%) as measured by double partial Mayo remission
  • Stelara is a biologic targeting IL-12 and IL -23- approved to treat mod. to sev. plaque psoriasis in the EU. This marketing authorization follows EMA’s CHMP positive opinion received on July 25- 2019

Click here to­ read full press release/ article

Ref: Janssen | Image: Janssen


Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions